Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1440 | Thyroid (non-cancer) | ECE2017

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Krajewska Jolanta , Kukulska Aleksandra , Handkiewicz-Junak Daria , Paliczka-Cieslik Ewa , Olczyk Tomasz , Gawlik Tomasz , Ledwon Aleksandra , Michalik Barbara , Jarzab Barbara

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

ea0041s6.3 | Characterization and treatment of thyroid cancer | ECE2016

Dynamic risk stratification in the follow up of thyroid cancer

Jarzab Barbara

The discussion which prognostic factors are the most reliable to adequately assess the risk of cancer related death and relapse in differentiated thyroid cancers [DTC] is ongoing. To date, age at diagnosis and distant metastases were considered as the most important risk factors. Among other factors, that may influence both overall and disease free survival, were male sex, some histopathological features such as: tumor diameter, tumor grade, aggressive histotype, extrathyroida...

ea0016s27.3 | Nodules and more: new aspects of thyroid disorders | ECE2008

Therapeutic options and dilemmas in medullary thyroid carcinoma

Jarzab Barbara

Analysis of RET germline mutations, now a routine element of diagnostic algorithm in medullary thyroid carcinoma (MTC), influences follow up of MTC patients but at present has less impact on treatment modalities, which are the same in hereditary and sporadic disease. Microarray analyses confirm that molecular profile is rather similar in both MTC forms.In hereditary MTC, RET mutation screening in families at risk allows to find asymptomatic mutation carr...

ea0035p550 | Endocrine tumours and neoplasia | ECE2014

The effectiveness of yttrium90/lutetium177-labeled somatostatin analogues treatment in functional pNETs

Michalik Barbara , Handkiewicz-Junak Daria , Hasse-Lazar Kornelia , Jarzab Barbara

Introduction: Therapy with somatostatin analouges is usually ineffective to remove hormonal symptoms in patients with functional pancreatic neuroendocrine tumors (pNET). Alternative treatment modalities, to control symptoms of excessive hormonal production, are necessary. Thus, the aim of our study was to evaluate results of radiopeptide treatment in patient with functional pNET.Materials and methods: 92 patients with pNET (49 women and 43 men, median ag...

ea0049ep1420 | Thyroid (non-cancer) | ECE2017

Prognostic value of preoperative serum calcitonin concentration on primary surgery outcomes in medullary thyroid cancer

Gawlik Tomasz , Kukulska Aleksandra , Wygoda Zbigniew , Krajewska Jolanta , Stobiecka Ewa , Czarniecka Agnieszka , Jarzab Barbara

Calcitonin assessment in thyroid diseases is recommended when medullary thyroid cancer (MTC) is suspected in fine needle biopsy, as well as in ‘suspicious for a follicular neoplasm’ class, especially oxyphilic type, in patients with germinal RET proto-oncogene mutation and in nondiagnostic biopsy when no surgical treatment is planned. This assessment is also suggested before any planned thyroid surgery to exclude MTC. Beyond diagnosis confirmation it is also suggeste...

ea0041gp198 | Thyroid - Basic | ECE2016

Differences in gene–gene interactions in Graves’ disease patients stratified by the age of diagnosis

Jurecka-Lubieniecka Beata , Bednarczuk Tomasz , Ploski Rafal , Kula Dorota , Tukiendorf Andrzej , Kolosza Zofia , Jarzab Barbara

Background: The genetic predisposition of Graves’ disease (GD) was proved by the identification of genes with substantial, non-interactive effects on the disease process. It is known, however, that genetic interactions significantly increase the likelihood of immune-tolerance-related complex diseases like allergic asthma and rheumatoid arthritis. In the present study we analyzed the effects of interactions of multiple loci on the genetic predisposition to GD patients....

ea0032p216 | Clinical case reports – Pituitary/Adrenal | ECE2013

Long-term treatment with octreotide in a patient with malignant pheochromocytoma: impact on survival and time to tumor progression

Gruszka Anna , Zieleniewski Wojciech , Kotecka-Blicharz Agnieszka , Jarzab Barbara , Kunert-Radek Jolanta

Introduction: Pheochromocytomas are rare neuroendocrine tumors arising from chromaffin cells of the adrenal medulla. Approximately 10% of all pheochromocytomas are malignant. There is no effective therapy for malignant pheochromocytoma (MAL-PHEO) and the overall prognosis is poor.Case report: We report 22-year survival with MAL-PHEO in a patient treated with several surgeries, 131I-metaiodobenzylguanidine and, subsequently, with long-acting fo...

ea0022p449 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Pheochromocytomas in the RET protooncogene mutations carriers

Hasse-Lazar Kornelia , Krawczyk Aleksandra , Szpak-Ulczok Sylwia , Pawlaczek Agnieszka , Ziaja Jacek , Jarzab Barbara

Mutations in the RET protooncogene cause familial cases of medullary thyroid cancer, which in some cases coexists with pheochromocytoma and primary hyperparathyreoidism as the MEN2A syndrome.Aim of the study: Evaluation of frequency of pheochromocytomas and their clinical course in the RET protooncogene mutations carriers.Material: One hundred and seventy nine patients, among them 109 probands and 70 family members in...

ea0014p369 | (1) | ECE2007

CRABP2 expression is up-regulated in parathyroid adenomas in correlation with HRPT2 down-regulation

Zebracka Jadwiga , Waler Janusz , Kowalska Malgorzata , Gala Grzegorz , Gawrychowski Jacek , Jarzab Barbara

Introduction: The molecular events involved in the formation of parathyroid adenomas are not well understood. Two genes, cyclin D1 (CCND1) and MEN-1, have been established as having major roles in parathyroid tumorigenesis. Tumor suppressor gene HRPT2 is frequently mutated in parathyroid carcinoma. The aim of our study was to analyze HRPT2 expression in parathyroid adenomas and in residual normal/atrophic parathyroid tissue and to relate it to other...

ea0092ps1-01-09 | Cancer | ETA2023

Risk of renal adverse effects in patients with advanced thyroid cancer who are undergoing radiological monitoring, with a particular focus on patients receiving tyrosine kinase inhibitors

Haras-Gil Malgorzata , Samborski Konrad , Ledwon Aleksandra , Kolton Magdalena , Handkiewicz-Junak Daria , Jarzab Barbara , Krajewska Jolanta

Introduction: Systemic treatment of advanced progressing thyroid cancer (TC) is based on molecularly targeted therapy with tyrosine kinase inhibitors (TKIs), mainly inhibitors targeting vascular endothelial growth factor receptors (VEGFR). Such treatment is related to numerous side effects. However, the relationship between TKIs and renal adverse events (RAEs) is unclear. VEGFR inhibitors are associated with proteinuria. In some patients, increased serum creatinine level and t...